T2 Biosystems' Q3 Loss Up on Marketing, Commercialization Costs | GenomeWeb

NEW YORK (GenomeWeb) – T2 Biosystems reported after the close of the market yesterday a rise in its net loss for the third quarter as costs increased amid the ongoing rollout of its Candida test.

For the three-month period ended Sept. 30, the company posted revenues in the quarter of roughly $1 million, $245,000 from product sales and $804,000 in research revenues, compared with no revenues in the third quarter of 2014. Wall Street analysts, on average, had anticipated revenues of around $700,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.